The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
The rise of fragment-based drug discovery
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B. A., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., et al. (2005) · Nature · doi:10.1038/nature03579 · Cited by 3,416
The influence of drug-like concepts on decision-making in medicinal chemistry
Leeson, P. D., & Springthorpe, B. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2445 · Cited by 2,403
Discovering High-Affinity Ligands for Proteins: SAR by NMR
Shuker, S. B., Hajduk, P. J., Meadows, R. P., & Fesik, S. W. (1996) · Science · doi:10.1126/science.274.5292.1531 · Cited by 2,041
Reaching for high-hanging fruit in drug discovery at protein–protein interfaces
Wells, J. A., & McClendon, C. L. (2007) · Nature · doi:10.1038/nature06526 · Cited by 1,960
Ligand efficiency: a useful metric for lead selection
Hopkins, A. L., Groom, C. R., & Alex, A. (2004) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03069-7 · Cited by 1,846
A ‘Rule of Three’ for fragment-based lead discovery?
Congreve, M., Carr, R., Murray, C., & Jhoti, H. (2003) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02831-9 · Cited by 1,354
Self-citationA decade of fragment-based drug design: strategic advances and lessons learned
Hajduk, P. J., & Greer, J. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2220 · Cited by 1,064
Page, M. I., & Jencks, W. P. (1971) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.68.8.1678 · Cited by 1,014
Generation of a Set of Simple, Interpretable ADMET Rules of Thumb
Gleeson, M. P. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701122q · Cited by 969
Physiochemical drug properties associated with in vivo toxicological outcomes
Hughes, J. D., Blagg, J., Price, D. A., Bailey, S., DeCrescenzo, G. A., Devraj, R. V., Ellsworth, E., Fobian, Y. M., Gibbs, M. E., Gilles, R. W., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.07.071 · Cited by 946
On the attribution and additivity of binding energies
Jencks, W. P. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.7.4046 · Cited by 912
Molecular Complexity and Its Impact on the Probability of Finding Leads for Drug Discovery
Hann, M. M., Leach, A. R., & Harper, G. (2001) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci000403i · Cited by 877
The Design of Leadlike Combinatorial Libraries
Teague, S. J., Davis, A. M., Leeson, P. D., & Oprea, T. (1999) · Angewandte Chemie International Edition · doi:10.1002/(sici)1521-3773(19991216)38:24<3743::aid-anie3743>3.0.co;2-u · Cited by 870
The maximal affinity of ligands
Kuntz, I. D., Chen, K., Sharp, K. A., & Kollman, P. A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.18.9997 · Cited by 849
Rees, D. C., Congreve, Murray, C. W., & Carr, R. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1467 · Cited by 798
Self-citationErlanson, D. A., McDowell, R. S., & O'Brien, T. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm040031v · Cited by 642
Recent Developments in Fragment-Based Drug Discovery
Congreve, M., Chessari, G., Tisi, D., & Woodhead, A. J. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm8000373 · Cited by 611
A Comparison of Physiochemical Property Profiles of Development and Marketed Oral Drugs
Wenlock, M. C., Austin, R. P., Barton, P., Davis, A. M., & Leeson, P. D. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm021053p · Cited by 546
Ligand efficiency indices as guideposts for drug discovery
Abad-Zapatero, C., & Metz, J. T. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03386-6 · Cited by 527
Fink, T., & Reymond, J.-L. (2007) · Journal of Chemical Information and Modeling · doi:10.1021/ci600423u · Cited by 457
An Inhibitor of FtsZ with Potent and Selective Anti-Staphylococcal Activity
Haydon, D. J., Stokes, N. R., Ure, R., Galbraith, G., Bennett, J. M., Brown, D. R., Baker, P. J., Barynin, V. V., Rice, D. W., Sedelnikova, S. E., et al. (2008) · Science · doi:10.1126/science.1159961 · Cited by 452
Fragment-Based Lead Discovery Using X-ray Crystallography
Hartshorn, M. J., Murray, C. W., Cleasby, A., Frederickson, M., Tickle, I. J., & Jhoti, H. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0495778 · Cited by 422
Self-citationCharacteristic Physical Properties and Structural Fragments of Marketed Oral Drugs
Vieth, M., Siegel, M. G., Higgs, R. E., Watson, I. A., Robertson, D. H., Savin, K. A., Durst, G. L., & Hipskind, P. A. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm030267j · Cited by 359
Virtual Exploration of the Small‐Molecule Chemical Universe below 160 Daltons
Fink, T., Bruggesser, H., & Reymond, J. (2005) · Angewandte Chemie International Edition · doi:10.1002/anie.200462457 · Cited by 353
Fragment-based lead discovery: leads by design
Carr, R. A. E., Congreve, M., Murray, C. W., & Rees, D. C. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03511-7 · Cited by 343
Self-citationWyatt, P. G., Woodhead, A. J., Berdini, V., Boulstridge, J. A., Carr, M. G., Cross, D. M., Davis, D. J., Devine, L. A., Early, T. R., Feltell, R. E., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800382h · Cited by 340
Keynote review: Structural biology and drug discovery
Congreve, M., Murray, C. W., & Blundell, T. L. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03484-7 · Cited by 338
Self-citationThe price of lost freedom: entropy of bimolecular complex formation
Finkelstein, A. V., & Janin, J. (1989) · "Protein Engineering, Design and Selection" · doi:10.1093/protein/3.1.1 · Cited by 328
Studies Leading to Potent, Dual Inhibitors of Bcl-2 and Bcl-xL
Bruncko, M., Oost, T. K., Belli, B. A., Ding, H., Joseph, M. K., Kunzer, A., Martineau, D., McClellan, W. J., Mitten, M., Ng, S.-C., et al. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm061152t · Cited by 304
Park, C.-M., Bruncko, M., Adickes, J., Bauch, J., Ding, H., Kunzer, A., Marsh, K. C., Nimmer, P., Shoemaker, A. R., Song, X., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800669s · Cited by 300
Discovery of a Potent Inhibitor of the Antiapoptotic Protein Bcl-x L from NMR and Parallel Synthesis
Petros, A. M., Dinges, J., Augeri, D. J., Baumeister, S. A., Betebenner, D. A., Bures, M. G., Elmore, S. W., Hajduk, P. J., Joseph, M. K., Landis, S. K., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0507532 · Cited by 292
Ertl, P. (2003) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci0255782 · Cited by 292
Fragment-Based Drug Design: How Big Is Too Big?
Hajduk, P. J. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060511h · Cited by 265
Library Design for Fragment Based Screening
Schuffenhauer, A., Ruedisser, S., Marzinzik, A., Jahnke, W., Selzer, P., & Jacoby, E. (2005) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026054637700 · Cited by 203
Murray, C. W., & Verdonk, M. L. (2002) · Journal of Computer-Aided Molecular Design · doi:10.1023/a:1022446720849 · Cited by 200
Self-citationFragment screening: an introduction
Leach, A. R., Hann, M. M., Burrows, J. N., & Griffen, E. J. (2006) · Molecular BioSystems · doi:10.1039/b610069b · Cited by 163
Deconstructing fragment-based inhibitor discovery
Babaoglu, K., & Shoichet, B. K. (2006) · Nature Chemical Biology · doi:10.1038/nchembio831 · Cited by 162
Identification of Inhibitors of Protein Kinase B Using Fragment-Based Lead Discovery
Saxty, G., Woodhead, S. J., Berdini, V., Davies, T. G., Verdonk, M. L., Wyatt, P. G., Boyle, R. G., Barford, D., Downham, R., Garrett, M. D., et al. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070091b · Cited by 141
Wendt, M. D., Wang, S., Kunzer, A. R., McClellan, W. J., Bruncko, M., Oost, T. K., Ding, H., Joseph, M. K., Zhang, H., Nimmer, P. M., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm050754u · Cited by 139
Ciulli, A., Williams, G., Smith, A. G., Blundell, T. L., & Abell, C. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060490r · Cited by 137
Fragment-based approaches to enzyme inhibition
Ciulli, A., & Abell, C. (2007) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2007.09.003 · Cited by 109
Antibacterial alkoxybenzamide inhibitors of the essential bacterial cell division protein FtsZ
Czaplewski, L. G., Collins, I., Boyd, E. A., Brown, D., East, S. P., Gardiner, M., Fletcher, R., Haydon, D. J., Henstock, V., Ingram, P., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.11.021 · Cited by 91
Molecular recognition: the fragment approach in lead generation
Fattori, D. (2004) · Drug Discovery Today · doi:10.1016/s1359-6446(03)03007-1 · Cited by 82
Adrian, G., Marcel, V., Robert, B., et al. (2007) · Current Topics in Medicinal Chemistry · doi:10.2174/156802607781696819 · Cited by 62
Fragment-Based Design of Small Molecule X-Linked Inhibitor of Apoptosis Protein Inhibitors
Huang, J., Zhang, Z., Wu, B., Cellitti, J. F., Zhang, X., Dahl, R. S., Shiau, C., Welsh, K., Emdadi, A., Stebbins, J. L., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm8006992 · Cited by 56
Fragment-based activity space: smaller is better
Hesterkamp, T., & Whittaker, M. A. (2008) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2008.02.005 · Cited by 55
The art and practice of structure-based drug design: A molecular modeling perspective
(1996) · doi:10.1002/(sici)1098-1128(199601)16:1<3::aid-med1>3.0.co;2-6
Cited by
Chemistry and Biology Of Multicomponent Reactions
Dömling, A., Wang, W., & Wang, K. (2012) · Chemical Reviews · doi:10.1021/cr100233r · Cited by 2,547
Click Chemistry for Drug Development and Diverse Chemical–Biology Applications
Thirumurugan, P., Matosiuk, D., & Jozwiak, K. (2013) · Chemical Reviews · doi:10.1021/cr200409f · Cited by 1,896
Counting on natural products for drug design
Rodrigues, T., Reker, D., Schneider, P., & Schneider, G. (2016) · Nature Chemistry · doi:10.1038/nchem.2479 · Cited by 1,250
Vemurafenib: the first drug approved for BRAF-mutant cancer
Bollag, G., Tsai, J., Zhang, J., Zhang, C., Ibrahim, P., Nolop, K., & Hirth, P. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3847 · Cited by 822
Savelieff, M. G., Nam, G., Kang, J., Lee, H. J., Lee, M., & Lim, M. H. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00138 · Cited by 581
Metadata
- Authors
- Murray, C. W., & Rees, D. C.
- Venue
- Nature Chemistry
- Published
- 2009-06
- Volume
- 1
- Issue
- 3
- Pages
- 187-192
- ISSN
- 1755-4330 (ISSN-L)
- 1755-4349
- OpenAlex
- W2046813714
- Cited by
- 791
- References
- 48
- FWCI
- 32.19
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.